Rxivist logo

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates

By Julio C.C. Lorenzi, Pilar Mendoza, Yehuda Z. Cohen, Lilian Nogueira, Christy Lavine, Joseph Sapiente, Michael S. Seaman, Marie Wiatr, Nelly R. Mugo, Andrew Mujugira, Sinead Delany, Jairam Lingappa, Connie Celum, Marina Caskey, Michel C Nussenzweig

Posted 25 Sep 2020
bioRxiv DOI: 10.1101/2020.09.24.310938

Novel therapeutic and preventive strategies are needed to contain the HIV-1 epidemic. Broadly neutralizing human antibodies (bNAbs) with exceptional activity against HIV-1 are currently being tested in HIV-1 prevention trials. The selection of anti-HIV-1 bNAbs for clinical development was primarily guided by their in vitro neutralizing activity against HIV-1 Env pseudotyped viruses. Here we report on the neutralizing activity of 9 anti-HIV-1 bNAbs now in clinical development against 126 Clade A, C, D PBMC-derived primary African isolates. The neutralizing potency and breadth of the bNAbs tested was significantly reduced compared to pseudotyped viruses panels. The difference in sensitivity between pseudotyped viruses and primary isolates varied from 3-to nearly 100-fold depending on the bNAb and the HIV-1 clade. Thus, the neutralizing activity of bNAbs against primary African isolates differs and cannot be predicted from their activity against pseudovirus panels. The data have significant implications for interpreting the results of ongoing HIV-1 prevention trials. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 186 times
  • Download rankings, all-time:
    • Site-wide: 109,995
    • In immunology: 3,131
  • Year to date:
    • Site-wide: 107,997
  • Since beginning of last month:
    • Site-wide: 123,086

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News